Human Colorectal Cancer Stem Cell Line: A Novel Platform for Therapeutics and Research
This invention presents a novel human colon cancer stem cell clones (Tu-12, Tu-21, Tu-22), successfully expanded using epithelial stromal cell lines. This innovative cell line offers a robust in vitro model for studying cancer progression and developing new therapeutic strategies.
Description
The Tu-12, Tu-21, and Tu-22 human colon cancer stem cell lines are derived from tumor tissues collected from metastatic colon cancer patients. The method involves surgical removal of tumor tissues, followed by mincing and digestion using a two-step collagenase method and trypsin incubation. The dissociated tumor cells are then cultured on a monolayer of irradiated LA7 rodent epithelial feeder cells, enabling their efficient propagation. This technology allows for the expansion, identification, and isolation of cancer stem cells, which are crucial for drug screening and the discovery of new therapeutics. The clonally derived tumor cells exhibit key stem cell properties, including self-renewal and the ability to differentiate into mature colon cells. When transplanted into immunodeficient mice, these cells initiate tumors that closely resemble human colorectal cancer, demonstrating their tumorigenic potential in vivo.Applications
- Drug discovery and screening for novel colon cancer therapeutics.- Cancer research, particularly in understanding metastatic colon cancer progression.
- Development of in vitro and in vivo models for colon cancer studies.
- Potential for diagnostic tool development related to colon cancer stem cell identification.
Advantages
- Enables efficient expansion of human colon cancer stem cells.- Facilitates the identification and prospective isolation of cancer stem cells.
- Provides a platform for drug screening and the discovery of new cancer therapeutics.
- Demonstrates self-renewal and multipotency at the clonal level.
- Capable of initiating tumors in vivo that closely resemble human cancer.
Invention Readiness
The technology has generated substantial in vitro data, demonstrating the successful expansion, identification, and isolation of the novel human colon cancer stem cell lines, Tu-12, Tu-21, and Tu-22. Furthermore, these cells have been validated in vivo by showing their capacity to form tumors in immunodeficient mice that are morphologically identical to the original human tumors. Long-term cultures of these patient-specific tumor cells have been established, and their self-renewing and multipotency capacities have been functionally demonstrated.IP Status
Research ToolRelated Publication(s)
Odoux, C., Fohrer, H., Hoppo, T., Guzik, L., Stolz, D. B., Lewis, D. W., Gollin, S. M., Gamblin, T. C., Geller, D. A., & Lagasse, E. (2008). A Stochastic Model for Cancer Stem Cell Origin in Metastatic Colon Cancer. Cancer Research, 68(17), 6932–6941. https://doi.org/10.1158/0008-5472.can-07-5779